Bimodal release of olanzapine from lipid microspheres

Journal of Pharmaceutical Sciences

Volumn 99, Issue 10, 2010, Pages 4251-4260

  Fini, Adamo ^a   Cavallari, Cristina ^a   Ceschel, Giancarlo ^b   Rabasco, Antonio M ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Monteresearch   (Italy)

^c UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Bimodal release; Cutina stearic acid carrier; Olanzapine; Phase separation; Ultrasound assisted spray congealing

Indexed keywords

DRUG CARRIER; HYDROGENATED CASTOR OIL; LAURIC ACID; LIPID; MICROSPHERE; OLANZAPINE; PALMITIC ACID; STEARIC ACID;

ARTICLE; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; MELTING POINT; MISCIBILITY; PARTITION COEFFICIENT;

EID: 77957336605     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22146     Document Type: Article

References (20)

1. Liversidge G, Jenkins S, Merisko Liversidge E. 2006. Injectable nanoparticulate olanzapine formulations. USPTO Application #: 20060154918.
2. Detke H, McDonnell D, Kane J, Naber D, Sethuraman G, Lin D. 2008. Olanzapine long-acting injection for the maintenance treatment of schizophrenia: A 24-Week, Randomized, Double-Blind Trial. Data presented at Schizophrenia International Research Society Meeting, June 21-25.
3. Bourghol Hickey M, Remenar J. 2006. Novel olanzapine forms and related methods of treatment, US Patent 20060223794.
4. 2 precipitation. www.aapspharmsci.org/ abstracts/AM-2004 /AAPS2004-000993.
5. Greco K, Wright J. 2006. Aripiprazole, olanzapine and haloperidol pamoate salts, US Patent 6987111.
6. Keltjens R. 2005. Stable salts of olanzapine. PCT/EP2005/ 000835.
7. Keltjens R. 2008. Process for making olanzapine form 1. EP 733635.
8. Chakrabarti JK, Hotten TM, Tupper DE. 1993. 2-methylthienobenzodiazepine. US Patent 5,229,382.
9. San L, Casillas M, Ciudad A, Gilaberte I. 2008. Olanzapine orally disintegrating tablet: A review of efficacy and compliance. CNS Neurosci Ther 14:203-214.
10. Vidarsdottir S, Roelfsema F, Streefland T, Holst JJ, Rehfeld JF, Pijl H. 2010. Short-term treatment with olanzapine does not modulate gut hormone secretion: Olanzapine disintegrating versus standard tablets. Eur J Endocrinol 162:75-83.
11. Hatta K, Kawabata T, Yoshida K, Hamakawa H, Wakejima T, Furuta K, Nakamura M, Hirata T, Usui C, Nakamura H, Sawa Y. 2008. Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients. Gen Hosp Psychiatry 30:367-371.
12. Nahata T, Saini TR. 2008. Optimization of formulation variables for the development of long acting microsphere based depot injection of olanzapine. J Microencapsul 25:426-433.
13. Citrome L. 2009. Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: Focus on olanzapine long-acting injection. Patient Prefer Adherence 3:345-355.
14. Wagstaff AJ, Easton J, Scott LJ. 2005. Intramuscular Olanzapine: A review of its use in the management of acute agitation. CNS Drugs 19:147-164.
15. Akhras KS, Singh J, Gopal S, Schadrack J, Palumbo JM. 2009. Comparison of treatment completion rates for olanzapine pamoate and risperidone microspheres. Int J Clin Pract 63:962-963.
16. Kumar M, Misra A, Mishra AK, Mishra P, Pathak K. 2008. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J Drug Target 16:806-814.
17. Müller RH, Rühl D, Runge SA. 1996. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int J Pharm 144:115-121.
18. Vivek K, Reddy H, Murthy RS. 2007. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS PharmSciTech 8:E1-E9.
19. ALOGPS 2.1. 2006. http://146.107.217.178/la.
20. Khan N, Craig DQM. 2003. The influence of drug incorporation on the structure and release properties of solid dispersions in lipid matrices. J Control Release 93:355-368.